SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on December 24, 2014, by SIGA Technologies, Inc. The filing addresses a material event regarding the company's smallpox antiviral drug, Tecovirimat (ST-246), following discussions with the FDA and the Biomedical Advanced Research and Development Authority (BARDA).
Key Financial Metrics and Contract Impact
The filing details a significant adjustment to the provisional dosage and delivery schedule for Tecovirimat under the BARDA contract, resulting in the following financial implications:
- Q1 2015 Revenue Impact: Expected payments for deliveries in the first quarter of 2015 are reduced from approximately $89 million to approximately $48 million.
- Delivery Volume: Q1 2015 deliveries are expected to be approximately 360,000 courses, down from the previously contemplated 710,000 courses.
- 2016 Revenue Outlook: Deliveries of additional courses are expected to occur in 2016, with anticipated payments of approximately $41 million.
- Cost Contingency: SIGA may be required to supplement previously delivered courses to meet the new dosage requirements at no additional cost to BARDA.
The filing does not provide specific data on overall revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Operational Adjustments
The primary material change is the increase in the provisional dosage of Tecovirimat from 600 mg once daily to 600 mg twice daily (1,200 mg per day). This change necessitates an extension of the delivery schedule to BARDA. Consequently, the volume of courses delivered in Q1 2015 will be significantly lower, deferring a portion of the contract revenue to 2016.
Outlook, Risks, and Contingencies
Management anticipates that the BARDA contract will be modified to reflect the dosage increase and extended schedule. This modification is subject to approval by the Bankruptcy Court, which SIGA intends to seek in connection with the assumption of the contract under the Bankruptcy Code. The requirement to supplement previously delivered courses at no additional cost represents a potential cost contingency.
Key Facts for Investor Verification
- Confirmation of the Bankruptcy Court's approval of the modified BARDA contract.
- The final revised delivery schedule for Tecovirimat courses in 2015 and 2016.
- The total volume of previously delivered courses requiring supplementation and the associated cost impact on SIGA.
- Any further updates on the FDA's final dosage determination for Tecovirimat.